University of Pennsylvania

Penn engineers use lipid nanoparticles (LNPs) to target specific tissues, enhancing gene therapy and personalized medicine. Incorporating siloxane composites into LNPs, known as SiLNPs, significantly improves mRNA delivery, with some variants achieving up to 90% success in targeting lung tissue. SiLNPs also show potential in regenerative medicine and CRISPR-Cas-based gene editing.

Soligenix partners with Sterling Pharma Solutions to optimize synthetic hypericin production for HyBryte™ and SGX302, targeting CTCL and psoriasis. The collaboration aims to scale up manufacturing for clinical trials and commercialization, with a focus on reducing costs and advancing clinical programs.

Gene therapy shows promise for treating retinal diseases, but faces challenges like immune response and gene integration risks. Advances in delivery systems and viral vectors like adeno-associated viruses have improved efficacy, though nonviral methods are also explored. Clinical trials report improvements in visual function for inherited retinal diseases, but acquired diseases like glaucoma and age-related macular degeneration present different treatment needs. Regulatory approval and cost-effectiveness remain significant hurdles.

Halda Therapeutics appoints Christian Schade as CEO, aiming to advance RIPTAC™ therapeutics for cancer treatment.

Precision Neuroscience's Layer 7 Cortical Interface enables unprecedented brain signal mapping, decoding movement and speech with high accuracy, advancing brain-computer interface technology.

Naveris presents NavDx® test data at 2024 ASTRO, highlighting its role in managing HPV-driven oropharyngeal cancers, with studies showing its effectiveness in predicting treatment outcomes and guiding therapy adjustments.

The fifth Precision Medicine Conference at the University of Granada highlighted advances in innovative technologies for personalized treatment, with sessions on AI, nanotechnology, and various diseases. The event showcased the ibs.GRANADA's role in precision medicine research.

Cabaletta Bio (CABA) pioneers CD19 auto-CAR-T therapies for immunology diseases, facing volatility and challenges in manufacturing and patient enrollment. Despite hurdles, CABA's first-mover advantage in CAR-T for immunology could lead to durable drug-free remissions, potentially transforming treatment standards.

Alexander Fanaroff, MD, MHS, Assistant Professor of Medicine at the University of Pennsylvania, presents 'Rigorous Testing of Behavior Change Interventions: Lessons from the BE ACTIVE Randomized Clinical Trial' on Oct 18, 2024, 1-2 p.m. ET. Join via Zoom link with passcode 796831.

Jennifer Egan, Pulitzer Prize-winning author, speaks Oct. 30 at FAU’s MacArthur Campus as part of the Starry Nights series. The event, presented by the Wilkes Honors College and Osher Lifelong Learning Institute, includes public talks and interactive sessions with students. Egan’s visit marks the college’s 25th anniversary, with additional events featuring Ryan Serhant and Jeanette Walls.